42.15 USD
+0.01 (+0.02%)
We assign a fundamental rating of 4 out of 10 to SLGL. SLGL was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for SLGL as it has an excellent financial health rating, but there are worries on the profitability. SLGL is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year SLGL has reported negative net income.
In the past year SLGL has reported a negative cash flow from operations.
In the past 5 years SLGL reported 4 times negative net income.
In the past 5 years SLGL always reported negative operating cash flow.
1.2 Ratios
SLGL's Return On Assets of -8.68% is fine compared to the rest of the industry. SLGL outperforms 68.06% of its industry peers.
The Return On Equity of SLGL (-10.70%) is better than 72.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.68% | ||
| ROE | -10.7% | ||
| ROIC | N/A |
ROA(3y)-40.55%
ROA(5y)-33.3%
ROE(3y)-47.5%
ROE(5y)-38.86%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SLGL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SLGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SLGL has about the same amount of shares outstanding.
SLGL has more shares outstanding than it did 5 years ago.
SLGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 2.54 indicates that SLGL is not a great score, but indicates only limited risk for bankruptcy at the moment.
SLGL's Altman-Z score of 2.54 is fine compared to the rest of the industry. SLGL outperforms 63.35% of its industry peers.
SLGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.54 |
ROIC/WACCN/A
WACC8.6%
2.3 Liquidity
SLGL has a Current Ratio of 7.32. This indicates that SLGL is financially healthy and has no problem in meeting its short term obligations.
SLGL's Current ratio of 7.32 is fine compared to the rest of the industry. SLGL outperforms 71.73% of its industry peers.
SLGL has a Quick Ratio of 7.32. This indicates that SLGL is financially healthy and has no problem in meeting its short term obligations.
SLGL has a Quick ratio of 7.32. This is in the better half of the industry: SLGL outperforms 72.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.32 | ||
| Quick Ratio | 7.32 |
3. Growth
3.1 Past
The earnings per share for SLGL have decreased strongly by -54.91% in the last year.
SLGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 62.04%.
SLGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 64.25% yearly.
EPS 1Y (TTM)-54.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2030%
Revenue 1Y (TTM)62.04%
Revenue growth 3Y-43.83%
Revenue growth 5Y64.25%
Sales Q2Q%-92.54%
3.2 Future
SLGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.10% yearly.
SLGL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 94.55% yearly.
EPS Next Y97.17%
EPS Next 2Y38.97%
EPS Next 3Y10.07%
EPS Next 5Y15.1%
Revenue Next Year870.39%
Revenue Next 2Y327.87%
Revenue Next 3Y56.77%
Revenue Next 5Y94.55%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SLGL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLGL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.97%
EPS Next 3Y10.07%
5. Dividend
5.1 Amount
No dividends for SLGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:SLGL (1/2/2026, 8:00:02 PM)
42.15
+0.01 (+0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners26.46%
Inst Owner Change0%
Ins Owners5.14%
Ins Owner ChangeN/A
Market Cap117.60M
Revenue(TTM)18.97M
Net Income(TTM)-3.41M
Analysts82.86
Price Target51 (21%)
Short Float %1.93%
Short Ratio0.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)233.88%
Min Revenue beat(2)-15.77%
Max Revenue beat(2)483.54%
Revenue beat(4)2
Avg Revenue beat(4)119.23%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)483.54%
Revenue beat(8)4
Avg Revenue beat(8)101.43%
Revenue beat(12)5
Avg Revenue beat(12)51.51%
Revenue beat(16)7
Avg Revenue beat(16)32.65%
PT rev (1m)0%
PT rev (3m)733.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2222.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-70%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-86.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)225.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.69 | ||
| P/tB | 3.69 | ||
| EV/EBITDA | N/A |
EPS(TTM)-10.1
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.03
OCFYN/A
SpS8.58
BVpS11.43
TBVpS11.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.68% | ||
| ROE | -10.7% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-40.55%
ROA(5y)-33.3%
ROE(3y)-47.5%
ROE(5y)-38.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.32 | ||
| Quick Ratio | 7.32 | ||
| Altman-Z | 2.54 |
F-Score4
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)23.47%
Cap/Depr(5y)26.73%
Cap/Sales(3y)4.34%
Cap/Sales(5y)3.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2030%
EPS Next Y97.17%
EPS Next 2Y38.97%
EPS Next 3Y10.07%
EPS Next 5Y15.1%
Revenue 1Y (TTM)62.04%
Revenue growth 3Y-43.83%
Revenue growth 5Y64.25%
Sales Q2Q%-92.54%
Revenue Next Year870.39%
Revenue Next 2Y327.87%
Revenue Next 3Y56.77%
Revenue Next 5Y94.55%
EBIT growth 1Y71.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.8%
OCF growth 3YN/A
OCF growth 5YN/A
SOL-GEL TECHNOLOGIES LTD / SLGL FAQ
Can you provide the ChartMill fundamental rating for SOL-GEL TECHNOLOGIES LTD?
ChartMill assigns a fundamental rating of 4 / 10 to SLGL.
What is the valuation status for SLGL stock?
ChartMill assigns a valuation rating of 0 / 10 to SOL-GEL TECHNOLOGIES LTD (SLGL). This can be considered as Overvalued.
Can you provide the profitability details for SOL-GEL TECHNOLOGIES LTD?
SOL-GEL TECHNOLOGIES LTD (SLGL) has a profitability rating of 1 / 10.
Can you provide the financial health for SLGL stock?
The financial health rating of SOL-GEL TECHNOLOGIES LTD (SLGL) is 7 / 10.